Prasugrel : the real-life perspective

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 3, 2013, Pages 253-254

  Serebruany, Victor ^a   Atar, Dan ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antiplatelet therapy; Editorials; Insurance; Prasugrel; Registry

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG ELUTING STENT; EDITORIAL; HIGH RISK PATIENT; HUMAN; IMPLANTATION; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; THROMBOCYTE;

ANTIPLATELET THERAPY; EDITORIALS; INSURANCE; PRASUGREL; REGISTRY;

ACUTE CORONARY SYNDROME; BLUE CROSS BLUE SHIELD INSURANCE PLANS; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES;

EID: 84884469133     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000239     Document Type: Editorial

References (19)

1. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
2. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
5. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105.
6. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59:2159-2164.
7. Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATEPCI) trial. Circ Cardiovasc Interv. 2012;5:347-356.
8. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100-2109.
9. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY-ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-1309.
10. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg J, Widimsky P, Luo J, Miller DL, Goedicke J. A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. Am Heart J. 2011;161:650-656.e1.
11. Salisbury AC, Wang K, Cohen DJ, Li Y, Jones PG, Spertus JA. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circ Cardiovasc Qual Outcomes. 2013;6:27-34.
12. Sandhu A, Seth M, Dixon S, Share D, Wohns D, LaLonde T, Moscucci M, Riba AL, Grossman M, Gurm HS. Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Circ Cardiovasc Qual Outcomes. 2013;6:293-298.
13. The FDA prasugrel secondary review. http://www.fda.gov/ohrms/dockets/ac/ 09/briefing/2009-4412b1-00-FDA.htm. Accessed April 6, 2013.
14. Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med. 2010;170:1078-1080.
15. Serebruany VL. Prasugrel and cancer risks: potential causes and implications. Am J Med. 2009; 122:407-408.
16. Subramanyam M. Clinical development of biosimilars: an evolving landscape. Bioanalysis. 2013;5:575-586.
17. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J. 2011;162:733-739.
18. Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv. 2012;5:698-704.
19. Taegtmeyer AB, Kullak-Ublick GA, Widmer N, Falk V, Jetter A. Clinical usefulness of electronic drug-drug interaction checking in the care of cardiovascular surgery inpatients. Cardiology. 2012;123:219-222.